Journey to human clinical trials: Early-stage therapeutics development with Dr. Mads Daugaard

Today’s guest is Dr. Mads Daugaard. Mads is the Co-founder, President and Chief Scientific Officer at Canadian cancer therapeutics company, Rakovina Therapeutics, a Red Thread Ventures portfolio company. This is his third time on our podcast and in today’s session we focused on Rakovina’s 2022 progress, their partnership with the St.Baldrick's foundation, distinctions between first generation/next generation therapies, and their push to IND filing and human clinical trials. We hope you enjoy today’s discussion with Dr. Mads Daugaard!

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information can be found at www.rakovinatherapeutics.com, on LinkedIn, and on Twitter @rakovina_rkv.

Red Thread Ventures has featured Rakovina in multiple blog posts, head over to www.redthread.ventures/blog to learn more.